MA51558B1 - Dérivés de 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés similaires en tant que modulateurs du récepteur c5a pour le traitement de la vascularité et de maladies inflammatoires - Google Patents
Dérivés de 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés similaires en tant que modulateurs du récepteur c5a pour le traitement de la vascularité et de maladies inflammatoiresInfo
- Publication number
- MA51558B1 MA51558B1 MA51558A MA51558A MA51558B1 MA 51558 B1 MA51558 B1 MA 51558B1 MA 51558 A MA51558 A MA 51558A MA 51558 A MA51558 A MA 51558A MA 51558 B1 MA51558 B1 MA 51558B1
- Authority
- MA
- Morocco
- Prior art keywords
- derivatives
- pyrazolo
- pyrimidin
- tetrahydro
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
- Eye Examination Apparatus (AREA)
- Oscillators With Electromechanical Resonators (AREA)
Abstract
La présente invention concerne des dérivés de formule (i) dans laquelle le cycle a, x, y, z, ra, r1, r2, r3 et r4 sont tels que décrits dans la description, et en particulier, par exemple, des dérivés de 2,4,6,7-tétrahydro-pyrazolo [4,3-d]pyrimidin-5-one et des composés apparentés, leur préparation, leurs sels pharmaceutiquement acceptables, leur utilisation en tant que produits pharmaceutiques, des compositions pharmaceutiques contenant un ou plusieurs composés de formule (i), et en particulier leur utilisation en tant que modulateurs du récepteur c5a pour le traitement, par exemple, de la vascularite et de maladies inflammatoires.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018050598 | 2018-01-10 | ||
| PCT/EP2019/050372 WO2019137927A1 (fr) | 2018-01-10 | 2019-01-09 | Dérivés de 2,4,6,7-tétrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés apparentés en tant que modulateurs du récepteur c5a pour le traitement de la vascularite et de maladies inflammatoires |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51558A MA51558A (fr) | 2021-04-14 |
| MA51558B1 true MA51558B1 (fr) | 2022-12-30 |
Family
ID=65012016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51558A MA51558B1 (fr) | 2018-01-10 | 2019-01-09 | Dérivés de 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés similaires en tant que modulateurs du récepteur c5a pour le traitement de la vascularité et de maladies inflammatoires |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11608341B2 (fr) |
| EP (1) | EP3737684B1 (fr) |
| JP (1) | JP7014914B2 (fr) |
| KR (1) | KR102574564B1 (fr) |
| CN (1) | CN111566109B (fr) |
| AR (1) | AR114564A1 (fr) |
| AU (1) | AU2019207666B2 (fr) |
| BR (1) | BR112020013788A2 (fr) |
| CA (1) | CA3086310C (fr) |
| CL (1) | CL2020001817A1 (fr) |
| DK (1) | DK3737684T3 (fr) |
| EA (1) | EA202091641A1 (fr) |
| ES (1) | ES2933820T3 (fr) |
| HR (1) | HRP20221449T1 (fr) |
| HU (1) | HUE060515T2 (fr) |
| IL (1) | IL275868B2 (fr) |
| LT (1) | LT3737684T (fr) |
| MA (1) | MA51558B1 (fr) |
| MX (1) | MX2020007443A (fr) |
| MY (1) | MY198902A (fr) |
| PH (1) | PH12020500583B1 (fr) |
| PL (1) | PL3737684T3 (fr) |
| PT (1) | PT3737684T (fr) |
| RS (1) | RS63806B1 (fr) |
| SG (1) | SG11202006490YA (fr) |
| SI (1) | SI3737684T1 (fr) |
| TW (2) | TWI774905B (fr) |
| UA (1) | UA124694C2 (fr) |
| WO (1) | WO2019137927A1 (fr) |
| ZA (1) | ZA202004910B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737684B1 (fr) * | 2018-01-10 | 2022-11-16 | Idorsia Pharmaceuticals Ltd | Dérivés de 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés similaires en tant que modulateurs du récepteur c5a pour le traitement de la vascularité et de maladies inflammatoires |
| US11685729B2 (en) | 2018-01-19 | 2023-06-27 | Idorsia Pharmaceuticals Ltd. | C5a receptor modulators |
| CA3087886A1 (fr) | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | Modulateurs du recepteur c5a |
| HRP20240381T1 (hr) * | 2019-07-09 | 2024-06-07 | Idorsia Pharmaceuticals Ltd | Farmaceutski pripravak koji sadrži spoj tetrahidropirazolopirimidinona |
| US11193891B2 (en) * | 2019-12-20 | 2021-12-07 | Robert Bosch Gmbh | Receptors and spacers for a fluorescence-based lead ion chemosensor |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003218374A1 (en) | 2002-03-28 | 2003-10-13 | Neurogen Corporation | Substituted tetrahydroisoquinolines as c5a receptor modulators |
| AU2003269850A1 (en) * | 2002-10-08 | 2004-05-04 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
| US7906528B2 (en) * | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| PT2585064T (pt) | 2010-06-24 | 2017-08-08 | Chemocentryx Inc | Antagonistas do c5ar |
| US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| TWI687220B (zh) * | 2013-03-01 | 2020-03-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| JP6417419B2 (ja) | 2013-09-04 | 2018-11-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 免疫調節剤として有用な化合物 |
| HRP20181052T1 (hr) | 2013-09-06 | 2018-09-07 | Aurigene Discovery Technologies Limited | Derivati 1,2,4-oksadiazola kao imunomodulatori |
| WO2015044900A1 (fr) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Composés immunomodulateurs thérapeutiques |
| CA2960436C (fr) * | 2014-09-16 | 2021-01-05 | Gilead Sciences, Inc. | Formes solides d'un modulateur de recepteurs de type toll |
| US9682940B2 (en) | 2015-08-25 | 2017-06-20 | Janssen Pharmaceutica Nv | Indazole derivatives useful as CB-1 inverse agonists |
| EP3737684B1 (fr) * | 2018-01-10 | 2022-11-16 | Idorsia Pharmaceuticals Ltd | Dérivés de 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés similaires en tant que modulateurs du récepteur c5a pour le traitement de la vascularité et de maladies inflammatoires |
| CA3087886A1 (fr) | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | Modulateurs du recepteur c5a |
| US11685729B2 (en) | 2018-01-19 | 2023-06-27 | Idorsia Pharmaceuticals Ltd. | C5a receptor modulators |
| HRP20240381T1 (hr) | 2019-07-09 | 2024-06-07 | Idorsia Pharmaceuticals Ltd | Farmaceutski pripravak koji sadrži spoj tetrahidropirazolopirimidinona |
-
2019
- 2019-01-09 EP EP19700269.4A patent/EP3737684B1/fr active Active
- 2019-01-09 PT PT197002694T patent/PT3737684T/pt unknown
- 2019-01-09 MY MYPI2020003550A patent/MY198902A/en unknown
- 2019-01-09 HU HUE19700269A patent/HUE060515T2/hu unknown
- 2019-01-09 TW TW108100804A patent/TWI774905B/zh active
- 2019-01-09 TW TW111127843A patent/TWI839788B/zh active
- 2019-01-09 ES ES19700269T patent/ES2933820T3/es active Active
- 2019-01-09 BR BR112020013788-0A patent/BR112020013788A2/pt active IP Right Grant
- 2019-01-09 WO PCT/EP2019/050372 patent/WO2019137927A1/fr not_active Ceased
- 2019-01-09 DK DK19700269.4T patent/DK3737684T3/da active
- 2019-01-09 JP JP2020538035A patent/JP7014914B2/ja active Active
- 2019-01-09 UA UAA202004963A patent/UA124694C2/uk unknown
- 2019-01-09 SG SG11202006490YA patent/SG11202006490YA/en unknown
- 2019-01-09 LT LTEPPCT/EP2019/050372T patent/LT3737684T/lt unknown
- 2019-01-09 MA MA51558A patent/MA51558B1/fr unknown
- 2019-01-09 RS RS20221138A patent/RS63806B1/sr unknown
- 2019-01-09 KR KR1020207022343A patent/KR102574564B1/ko active Active
- 2019-01-09 CA CA3086310A patent/CA3086310C/fr active Active
- 2019-01-09 AR ARP190100043A patent/AR114564A1/es unknown
- 2019-01-09 EA EA202091641A patent/EA202091641A1/ru unknown
- 2019-01-09 SI SI201930400T patent/SI3737684T1/sl unknown
- 2019-01-09 HR HRP20221449TT patent/HRP20221449T1/hr unknown
- 2019-01-09 AU AU2019207666A patent/AU2019207666B2/en active Active
- 2019-01-09 CN CN201980007596.9A patent/CN111566109B/zh active Active
- 2019-01-09 PL PL19700269.4T patent/PL3737684T3/pl unknown
- 2019-01-09 MX MX2020007443A patent/MX2020007443A/es unknown
- 2019-01-09 PH PH1/2020/500583A patent/PH12020500583B1/en unknown
- 2019-01-09 US US16/961,600 patent/US11608341B2/en active Active
-
2020
- 2020-07-06 IL IL275868A patent/IL275868B2/en unknown
- 2020-07-08 CL CL2020001817A patent/CL2020001817A1/es unknown
- 2020-08-07 ZA ZA2020/04910A patent/ZA202004910B/en unknown
-
2022
- 2022-12-20 US US18/084,911 patent/US20230192708A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51558B1 (fr) | Dérivés de 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés similaires en tant que modulateurs du récepteur c5a pour le traitement de la vascularité et de maladies inflammatoires | |
| MA56883B1 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA58181B1 (fr) | Composés tricycliques substitués | |
| MA52360B1 (fr) | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
| MA33239B1 (fr) | 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MA29926B1 (fr) | Derives de pyrazine | |
| MA30403B1 (fr) | Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
| MA57000B1 (fr) | Dérivés d'alpha-d-galactopyranoside | |
| MA33768B1 (fr) | Triazolopyridines | |
| MA44674A (fr) | Inhibiteurs de bromodomaine | |
| MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
| MA33726B1 (fr) | Composes de dioxyde d'iminothiadiazine comme inhibiteurs de bace, compositions et leur utlisation | |
| MA27568A1 (fr) | Derives de pyrrolopyrimidine | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA35422B1 (fr) | Imidazopyridazines amino-substituees | |
| MA30142B1 (fr) | Agonistes du recepteur de neuropeptide-2 | |
| MA27775A1 (fr) | Composes organiques | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 |